|
Volumn 32, Issue 3, 2010, Pages 510-511
|
Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus: Letters to the Editors
|
Author keywords
[No Author keywords available]
|
Indexed keywords
INFLIXIMAB;
TACROLIMUS;
TUMOR NECROSIS FACTOR ALPHA;
COLON MUCOSA;
COLON RESECTION;
CYTOMEGALOVIRUS;
CYTOMEGALOVIRUS INFECTION;
DRUG EFFICACY;
DRUG SAFETY;
ENTERITIS;
HUMAN;
LETTER;
PRIORITY JOURNAL;
REMISSION;
TREATMENT OUTCOME;
ULCERATIVE COLITIS;
ANTI-INFLAMMATORY AGENTS;
ANTIBODIES, MONOCLONAL;
COLITIS, ULCERATIVE;
CYTOMEGALOVIRUS;
HUMANS;
TACROLIMUS;
TREATMENT OUTCOME;
|
EID: 77954319605
PISSN: 02692813
EISSN: 13652036
Source Type: Journal
DOI: 10.1111/j.1365-2036.2010.04372.x Document Type: Letter |
Times cited : (8)
|
References (6)
|